CN115246781A - 一种沙芬酰胺的制备方法 - Google Patents
一种沙芬酰胺的制备方法 Download PDFInfo
- Publication number
- CN115246781A CN115246781A CN202110465135.5A CN202110465135A CN115246781A CN 115246781 A CN115246781 A CN 115246781A CN 202110465135 A CN202110465135 A CN 202110465135A CN 115246781 A CN115246781 A CN 115246781A
- Authority
- CN
- China
- Prior art keywords
- fluorobenzyl
- oxy
- solvent
- room temperature
- safinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 title claims abstract description 37
- 229950002652 safinamide Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 51
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 35
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- -1 (4- (chloromethyl) phenoxy) methyl Chemical group 0.000 claims description 15
- DNKSIIHRKWTIRH-UHFFFAOYSA-N 4-[(3-fluorophenyl)methoxy]benzaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(C=O)=CC=2)=C1 DNKSIIHRKWTIRH-UHFFFAOYSA-N 0.000 claims description 14
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 14
- NKLDZRNXUOAPLY-UHFFFAOYSA-N 1-(chloromethyl)-4-[(3-fluorophenyl)methoxy]benzene Chemical compound FC1=CC=CC(COC=2C=CC(CCl)=CC=2)=C1 NKLDZRNXUOAPLY-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- FIAINKIUSZGVGX-DKWTVANSSA-N [(2s)-1-amino-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.C[C@H](N)C(N)=O FIAINKIUSZGVGX-DKWTVANSSA-N 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- XBDXMDVEZLOGMC-UHFFFAOYSA-N 1-(chloromethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CCl)=C1 XBDXMDVEZLOGMC-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- XXFAKYKJDDMEGJ-UHFFFAOYSA-N 1-fluoro-3-(fluoromethyl)benzene Chemical compound FCC1=CC=CC(F)=C1 XXFAKYKJDDMEGJ-UHFFFAOYSA-N 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- RWBBDSAYSNJJHM-UHFFFAOYSA-N 5-methyl-3-oxo-2-phenyl-1h-pyrazole-4-carbaldehyde Chemical compound O=C1C(C=O)=C(C)NN1C1=CC=CC=C1 RWBBDSAYSNJJHM-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JTEAJDZCZAAZJA-UHFFFAOYSA-N [4-[(3-fluorophenyl)methoxy]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC(F)=C1 JTEAJDZCZAAZJA-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种沙芬酰胺的制备方法,本发明沙芬酰胺的制备方法反应条件温和,收率高,该合成方法具有操作简便,后处理简单,成本低,对环境友好等特点,并可以获得高质量的目标产物,有利于工业生产。
Description
技术领域
本发明涉及有机合成技术领域,具体涉及一种沙芬酰胺的制备方法。
背景技术
沙芬酰胺甲磺酸盐(Safinamidemesilate),化学名为(S)-2-[4-(3-氟苄氧基)苄胺基]丙酰胺甲磺酸盐,是由 Newron制药公司研发的抗帕金森病药。本品具有多种作用机制,不仅可高选择性及可逆性抑制单胺氧化酶B(MAO-B),还可以抑制多巴胺再摄取,阻断电压依赖的钠通道、调节钙通道,从而抑制谷氨酸释放。沙芬酰胺的中枢神经系统生物利用度高,临床显示可以提高帕金森病患者的运动和认知功能,防止患者出现运动障碍,且具有良好的耐受性
发明内容
本发明的技术方案是提供一种制备沙芬酰胺的新方法。本发明的制备方法条件温和、收率高、后处理简便、制得的产品纯度高、生产成本低、适合工业化生产。
本发明提供了一种沙芬酰胺的制备方法,包括步骤d:
在一些实施方案中,所述的沙芬酰胺的制备方法,其采用1-((4-(氯甲基)苯氧基)甲基)-3-氟苯与L-丙氨酰胺在有机溶剂和碱性物质存在下反应制得沙芬酰胺。
在一些典型的实施方案中,所述沙芬酰胺的制备方法,所采用的碱性物质选自碳酸钾、碳酸钠、三乙胺和二异丙基乙胺中的一种或两种;优选为三乙胺。
在一些典型的实施方案中,所述沙芬酰胺的制备方法,所采用的有机溶剂选自乙腈、N-甲基吡咯烷酮、 N,N-二甲基甲酰胺和二甲基亚砜的一种或者多种;优选为N,N-二甲基甲酰胺。
在一些典型的实施方案中,所述沙芬酰胺的制备方法,所采用的温度选自0~100℃;优选为0~30℃。
在一些典型的实施方案中,所述沙芬酰胺的制备方法,所采用的L-丙氨酰胺可以其酸式盐的形式使用或者是其游离碱;优选L-丙氨酰胺盐酸盐。
进一步的,本发明提供的一种沙芬酰胺的制备方法,还包括以下步骤c:
在一些典型的实施方案中,所述的步骤c采用4-((3-氟苄基)氧基)苯甲醇在室温下以二氯甲烷作溶剂,与二氯亚砜反应得到1-((4-(氯甲基)苯氧基)甲基)-3-氟苯。
进一步的,本发明提供的一种沙芬酰胺的制备方法,还包括以下步骤b:
在一些典型的实施方案中,所述的步骤b采用4-((3-氟苄基)氧基)苯甲醛在室温下以甲醇作溶剂,与硼氢化钠反应得到4-((3-氟苄基)氧基)苯甲醇。
进一步的,本发明提供的一种沙芬酰胺的制备方法,还包括以下步骤a:
在一些典型的实施方案中,所述的步骤a采用对羟基苯甲醛与3-氟氯苄在50~60℃下以N,N-二甲基甲酰胺作溶剂,碳酸钾作缚酸剂,反应得到4-((3-氟苄基)氧基)苯甲醛。
更进一步的,本发明提供的一种沙芬酰胺的制备方法,包括以下步骤:
步骤a:对羟基苯甲醛与3-氟氯苄在50~60℃下以N,N-二甲基甲酰胺作溶剂,碳酸钾作缚酸剂反应得到4-((3-氟苄基)氧基)苯甲醛;
步骤b:4-((3-氟苄基)氧基)苯甲醛在室温下以甲醇作溶剂,与硼氢化钠反应得到4-((3-氟苄基) 氧基)苯甲醇;
步骤c:4-((3-氟苄基)氧基)苯甲醇在室温下以二氯甲烷作溶剂,与二氯亚砜反应得到1-((4-(氯甲基)苯氧基)甲基)-3-氟苯;
步骤d:1-((4-(氯甲基)苯氧基)甲基)-3-氟苯与L-丙氨酰胺盐酸盐在室温下,以N,N-二甲基甲酰胺作溶剂,三乙胺作缚酸剂反应得到沙芬酰胺游离碱。
本发明还提供一种甲磺酸沙芬酰胺的合成方法,具体步骤如下:
步骤a:对羟基苯甲醛与3-氟氯苄在50~60℃下以N,N-二甲基甲酰胺作溶剂,碳酸钾作缚酸剂反应得到4-((3-氟苄基)氧基)苯甲醛;
步骤b:4-((3-氟苄基)氧基)苯甲醛在室温下以甲醇作溶剂,与硼氢化钠反应得到4-((3-氟苄基) 氧基)苯甲醇;
步骤c:4-((3-氟苄基)氧基)苯甲醇在室温下以二氯甲烷作溶剂,与二氯亚砜反应得到1-((4-(氯甲基)苯氧基)甲基)-3-氟苯;
步骤d:1-((4-(氯甲基)苯氧基)甲基)-3-氟苯与L-丙氨酰胺盐酸盐在室温下,以N,N-二甲基甲酰胺作溶剂,三乙胺作缚酸剂反应得到沙芬酰胺游离碱;
步骤e:沙芬酰胺游离碱在室温条件下,以乙酸乙酯作溶剂,与甲磺酸反应制得甲磺酸沙芬酰胺。
本发明通过上述制备工艺获得了如下的有益效果:本发明沙芬酰胺的制备方法反应条件温和,收率高,该合成方法具有操作简便,后处理简单,成本低,对环境友好等特点,并可以获得高质量的目标产物,有利于工业生产。
具体定义
室温:0~30℃
DMF:N,N-二甲基甲酰胺
DMSO:二甲基亚砜
DCM:二氯甲烷
EA:乙酸乙酯
TEA:三乙胺
具体实施方式
下面结合优选实施例对本发明作进一步说明,下述实施例仅用于说明本发明而并非对本发明的限制。
HPLC纯度测定条件:用十八烷基硅烷-五氟苯基键合硅胶为填充剂[ACEExcel3C18-PFP (4.6mm×150mm,3μm)或效能相当的色谱柱];以10mmol/L磷酸氢二钾缓冲液(取磷酸氢二钾1.74g,加水1000ml使溶解,用磷酸调节pH值至6.8)为流动相A,以甲醇为流动相B,按下表进行梯度洗脱;流速为每分钟0.8ml;柱温为35℃;检测波长为226nm。
实施例1 4-((3-氟苄基)氧基)苯甲醛的合成
反应瓶中加入对羟基苯甲醛(10.0g,81.9mmol),无水碳酸钾(12.4g,90.1mmol)和40mlDMF,室温搅拌15min,3-氟氯苄(12.1g,83.5mmol)用10mlDMF溶解后,滴加至反应瓶中,升温至50~60℃反应6h。TLC检测反应结束,抽滤,滤饼水洗,干燥得白色固体18.4g,收率97.6%,纯度:98.9%。1HNMR (DMSO-d6,500Hz)δ:9.91(s,1H),7.91~7.89(m,2H),7.48~7.44(m,1H),7.34~7.31(m,2H),7.24~7.16(m, 3H),5.27(s,2H).GC-MSm/z:230.0{[M]}.
实施例2(4-((3-氟苄基)氧基)苯基)甲醇的合成
反应瓶中加入4-((3-氟苄基)氧基)苯甲醛(5.0g,21.7mmol)和25ml甲醇,冰浴搅拌下,分批加入硼氢化钠(0.82g,21.7mmol),室温搅拌。反应完毕后,滴加50ml水,室温搅拌1h后抽滤,干燥得白色固体4.6g,收率91.2%,纯度:98.5%。1H-NMR(DMSO-d6,500Hz)δ:7.44~7.40(m,1H),7.29~7.26(m,4H), 7.15~7.12(m,1H),6.98~6.96(m,2H),5.12(s,2H),5.06~5.04(t,J=5.5Hz,1H),4.44~4.43(d,J=5.0Hz,2H). GC-MSm/z:232.0{[M]}.
实施例3 1-((4-(氯甲基)苯氧基)甲基)-3-氟苯的合成
反应瓶中加入(4-((3-氟苄基)氧基)苯基)甲醇(4.0g,17.2mmol)和40ml二氯甲烷,冰浴搅拌下,滴加SOCl2(2.7g,22.4mmol),冰浴反应。反应完毕后,反应液减压浓缩,得无色油状物4.0g,收率92.6%,纯度:98.8%,直接用于下步反应。1H-NMR(DMSO-d6,300Hz)δ:7.47~7.36(m,3H),7.30~7.27(d,J=8.1Hz, 2H),7.18~7.13(t,J=8.0Hz,1H),7.03(s,1H),7.00(s,1H),5.14(s,1H),4.72(s,1H).
实施例4(S)-2-((4-((3-氟苄基)氧基)苄基)氨基)丙酰胺的合成
反应瓶中加入1-((4-(氯甲基)苯氧基)甲基)-3-氟苯(3.0g,12.0mmol),L-丙氨酰胺盐酸盐(1.8g,14.4 mmol)、三乙胺(4.8g,47.9mmol)和30mlDMF,室温搅拌。反应完毕后,反应液滴加至90ml水中,冰浴搅拌1h后抽滤,干燥得白色固体2.7g,收率74.6%,纯度:98.0%。1H-NMR(DMSO-d6,500Hz)δ:9.07 (s,1H),8.00~7.62(s,2H),7.48~7.43(m,3H),7.32~7.28(t,J=10.0Hz,2H),7.18~7.14(t,J=10.0Hz,1H), 7.10~7.09(d,J=5.0Hz,2H),5.19(s,2H),4.10~4.01(m,2H),3.87~3.83(m,1H),1.48~1.47(d,J=5.0Hz,3H).ESI-MSm/z:303.2{[M+H]+}.
实施例5(S)-2-((4-((3-氟苄基)氧基)苄基)氨基)丙酰胺的合成
反应瓶中加入1-((4-(氯甲基)苯氧基)甲基)-3-氟苯(1.0g,4.0mmol),L-丙氨酰胺盐酸盐(0.6g,4.8 mmol)、碳酸钾(2.2g,16.0mmol)和10mlDMF,室温搅拌。反应完毕后,反应液滴加至30ml水中,冰浴搅拌1h后抽滤,干燥得白色固体0.68g,收率56%,纯度:94.6%。
实施例6(S)-2-((4-((3-氟苄基)氧基)苄基)氨基)丙酰胺的合成
反应瓶中加入1-((4-(氯甲基)苯氧基)甲基)-3-氟苯(1.0g,4.0mmol),L-丙氨酰胺盐酸盐(0.6g,4.8 mmol)、三乙胺(1.6g,12.0mmol)和10mlNMP,室温搅拌。反应完毕后,反应液滴加至30ml水中,冰浴搅拌1h后抽滤,干燥得白色固体0.78g,收率65%,纯度:96.8%。
实施例7(S)-2-((4-((3-氟苄基)氧基)苄基)氨基)丙酰胺甲磺酸盐的合成
反应瓶中加入(S)-2-((4-((3-氟苄基)氧基)苄基)氨基)丙酰胺(2.0g,6.6mmol)和40ml乙酸乙酯,升温至50~60℃搅拌溶清后趁热过滤,滤液中滴加甲磺酸(0.6g,6.6mmol),室温搅拌析晶1~2h后抽滤,干燥得粗品,白色固体2.5g,收率94.7%,纯度:99.5%。1H-NMR(DMSO-d6,500Hz)δ:9.07(s,2H),8.00~7.62 (s,2H),7.48~7.43(m,3H),7.32~7.28(t,J=10.0Hz,2H),7.18~7.14(t,J=10.0Hz,1H),7.10~7.09(d,J=5.0 Hz,2H),5.19(s,2H),4.10~4.01(m,2H),3.87~3.83(m,1H),2.43(s,3H),1.48~1.47(d,J=5.0Hz,3H). ESI-MSm/z:303.2{[M+H-CH3SO3H]+} 。
Claims (10)
2.如权利要求1所述的制备方法,其特征在于,所述的碱性物质选自碳酸钾、碳酸钠、三乙胺和二异丙基乙胺中的一种或两种;优选为三乙胺。
3.如权利要求1所述的制备方法,其特征在于,所述的有机溶剂选自乙腈、N-甲基吡咯烷酮、N,N-二甲基甲酰胺和二甲基亚砜的一种或者多种;优选为N,N-二甲基甲酰胺。
4.如权利要求1所述的制备方法,其特征在于,所采用的反应温度选自0~100℃;优选为0~30℃。
5.如权利要求1所述的制备方法,其特征在于,所采用的L-丙氨酰胺可以其酸式盐的形式使用或者是其游离碱;优选L-丙氨酰胺盐酸盐。
9.如权利要求1所述的制备方法,其特征在于,还包括以下步骤,
步骤a:对羟基苯甲醛与3-氟氯苄在50~60℃下以N,N-二甲基甲酰胺作溶剂,碳酸钾作缚酸剂反应得到4-((3-氟苄基)氧基)苯甲醛;
步骤b:4-((3-氟苄基)氧基)苯甲醛在室温下以甲醇作溶剂,与硼氢化钠反应得到4-((3-氟苄基)氧基)苯甲醇;
步骤c:4-((3-氟苄基)氧基)苯甲醇在室温下以二氯甲烷作溶剂,与二氯亚砜反应得到1-((4-(氯甲基)苯氧基)甲基)-3-氟苯;
步骤d:1-((4-(氯甲基)苯氧基)甲基)-3-氟苯与L-丙氨酰胺盐酸盐在室温下,以N,N-二甲基甲酰胺作溶剂,三乙胺作缚酸剂反应得到沙芬酰胺游离碱。
10.一种甲磺酸沙芬酰胺的制备方法,包括以下步骤,
步骤a:对羟基苯甲醛与3-氟氯苄在50~60℃下以N,N-二甲基甲酰胺作溶剂,碳酸钾作缚酸剂反应得到4-((3-氟苄基)氧基)苯甲醛;
步骤b:4-((3-氟苄基)氧基)苯甲醛在室温下以甲醇作溶剂,与硼氢化钠反应得到4-((3-氟苄基)氧基)苯甲醇;
步骤c:4-((3-氟苄基)氧基)苯甲醇在室温下以二氯甲烷作溶剂,与二氯亚砜反应得到1-((4-(氯甲基)苯氧基)甲基)-3-氟苯;
步骤d:1-((4-(氯甲基)苯氧基)甲基)-3-氟苯与L-丙氨酰胺盐酸盐在室温下,以N,N-二甲基甲酰胺作溶剂,三乙胺作缚酸剂反应得到沙芬酰胺游离碱;
步骤e:沙芬酰胺游离碱在室温条件下,以乙酸乙酯作溶剂,与甲磺酸反应制得甲磺酸沙芬酰胺。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110465135.5A CN115246781B (zh) | 2021-04-28 | 2021-04-28 | 一种沙芬酰胺的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110465135.5A CN115246781B (zh) | 2021-04-28 | 2021-04-28 | 一种沙芬酰胺的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115246781A true CN115246781A (zh) | 2022-10-28 |
CN115246781B CN115246781B (zh) | 2024-03-29 |
Family
ID=83696942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110465135.5A Active CN115246781B (zh) | 2021-04-28 | 2021-04-28 | 一种沙芬酰胺的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115246781B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110263573A1 (en) * | 2010-04-26 | 2011-10-27 | Cosimo Dolente | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
CN112010818A (zh) * | 2019-05-28 | 2020-12-01 | 广东东阳光药业有限公司 | 吗啉酰胺衍生物及其用途 |
-
2021
- 2021-04-28 CN CN202110465135.5A patent/CN115246781B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110263573A1 (en) * | 2010-04-26 | 2011-10-27 | Cosimo Dolente | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
CN102858778A (zh) * | 2010-04-26 | 2013-01-02 | 霍夫曼-拉罗奇有限公司 | 杂联芳基-环己基-四氮杂苯并[e]薁 |
CN112010818A (zh) * | 2019-05-28 | 2020-12-01 | 广东东阳光药业有限公司 | 吗啉酰胺衍生物及其用途 |
Non-Patent Citations (2)
Title |
---|
STOLFA, DIANA A.ETAL: "Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors", 《CHEMMEDCHEM》, pages 1256 * |
苗京等: "含查尔酮和罗丹宁乙酸结构化合物的合成及抗菌活性研究", 《延边大学医学学报》, pages 1 * |
Also Published As
Publication number | Publication date |
---|---|
CN115246781B (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5687205B2 (ja) | 2−アシルアミノ−3−ジフェニルプロパン酸の製造および分割のためのプロセス | |
KR102515430B1 (ko) | 글루포시네이트 제조 방법 | |
CN102209707A (zh) | 制备氨基酸衍生物的新方法 | |
CN102356063A (zh) | 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体 | |
WO2021143712A1 (zh) | 一种制备l-草铵膦中间体的方法 | |
CA2412047C (en) | Shortened synthesis of 3,3-diarylpropylamine derivatives | |
AU2010299483A1 (en) | Process for the preparation of sorafenib tosylate | |
CA2644624A1 (en) | A process for the preparation of (s)(+)-3-(aminomethyly)-5-methylhexanoic acid | |
CN102143937B (zh) | 制备光学活性(s)-(-)-2-(n-丙基氨基)-5-甲氧基四氢化萘和(s)-(-)-2-(n-丙基氨基)-5-羟基四氢化萘化合物的方法 | |
JP2011503053A (ja) | 2‐ヒドロキシ‐5‐フェニルアルキルアミノ安息香酸誘導体及びその塩の製造方法 | |
CN115246781B (zh) | 一种沙芬酰胺的制备方法 | |
EP1937662B1 (en) | Process for the preparation of duloxetine | |
CN110684043B (zh) | 一种c-n轴手性芳胺化合物及其制备方法 | |
EP3260442B1 (en) | Process for preparation of optically pure n-substituted-3-methoxypropionic acid derivatives | |
KR101525493B1 (ko) | 고순도 탐술로신 또는 이의 염 제조방법 | |
JP4406482B2 (ja) | 光学活性2−アミノシクロヘキサノール誘導体の製造法 | |
JPH10506653A (ja) | ヨウ素化造影剤の製造方法 | |
KR20170093017A (ko) | 베타-아미노-다이싸이오에스터 화합물의 제조방법 및 이에 의해 제조된 베타-아미노-다이싸이오에스터 화합물 | |
CN101139311A (zh) | 大规模制备维甲酰酚胺类化合物的方法 | |
CN111253369A (zh) | 一种苯磺酸盐、其制备方法及其在制备达比加群酯中的应用 | |
EP4257581A1 (en) | Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol | |
KR100683274B1 (ko) | 치환된 벤조피란 화합물의 제조방법 | |
CN109331868B (zh) | 一种苯甘氨酸类双官能团催化剂及其制备方法和应用 | |
WO2012027951A1 (zh) | 一种合成培南类药物的中间体及其制备方法和应用 | |
CN110894186B (zh) | 匹莫范色林及其中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |